Anzeige
Meldung des Tages: Der US-Öl-Trade, der mit der Geopolitik kollidiert!

Lucid Diagnostics News

Aktie
WKN:  ISIN:  US54948X1090 US-Symbol:  LUCD Branche:  Gesundheitswesen: Ausstattung u. Produkte Land:  USA
1,42 $
+0,065 $
+4,80%
1,2025 € 15.04.26
Depot/Watchlist
Marktkapitalisierung *
-
Streubesitz
36,90%
KGV
-2,43
Index-Zuordnung
-

Lucid Diagnostics News

27.08.25 - PR Newswire
Lucid Diagnostics to Participate in the Cantor Global Healthcare Conference 2025
Lucid Diagnostics to Participate in the Cantor Global Healthcare Conference 2025 PR Newswire
26.08.25 - PR Newswire
PAVmed Signs Letter of Intent to License Groundbreaking Endoscopic Esophageal Imaging Technology
PAVmed Signs Letter of Intent to License Groundbreaking Endoscopic Esophageal Imaging Technology PR Newswire
14.08.25 - PR Newswire
PAVmed Provides Business Update and Reports Second Quarter 2025 Financial Results
PAVmed Provides Business Update and Reports Second Quarter 2025 Financial Results PR Newswire
13.08.25 - PR Newswire
Lucid Diagnostics Provides Business Update and Reports Second Quarter 2025 Financial Results
Lucid Diagnostics Provides Business Update and Reports Second Quarter 2025 Financial Results PR Newswire
05.08.25 - PR Newswire
Lucid Diagnostics to Participate in Upcoming Investor Conferences
Lucid Diagnostics to Participate in Upcoming Investor Conferences PR Newswire
30.07.25 - PR Newswire
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025 PR Newswire
16.07.25 - PR Newswire
MolDX to Convene Expert Medical Panel on Medicare Local Coverage Determination (LCD) for Lucid Diagnostics' EsoGuard® Esophageal DNA Test
MolDX to Convene Expert Medical Panel on Medicare Local Coverage Determination (LCD) for Lucid Diagnostics' EsoGuard® Esophageal DNA Test PR Newswire
18.06.25 - PR Newswire
Major California Health System Launches Comprehensive Esophageal Precancer Testing Program Using Lucid Diagnostics' EsoGuard® Esophageal DNA Test
Major California Health System Launches Comprehensive Esophageal Precancer Testing Program Using Lucid Diagnostics' EsoGuard® Esophageal DNA Test PR Newswire
27.05.25 - PR Newswire
Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes
Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes PR Newswire
15.05.25 - PR Newswire
PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results
PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results PR Newswire
14.05.25 - PR Newswire
Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results
Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results PR Newswire
01.05.25 - PR Newswire
PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025
PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025 PR Newswire
30.04.25 - PR Newswire
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025 PR Newswire
24.04.25 - PR Newswire
NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD
NCI-​Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD PR Newswire

Newssuche

Videos

newspaper
07.04.26 +1,32%
Technical Trading: DAX Long kurzfristig
DAX Long Typ: Turbo Open End WKN: VJ9H40 Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »